(Approval lapsed) ONPATTRO Patisiran 10 mg/5 mL (2mg/mL) solution for intravenous infusion single-dose vial (USA)
Section 19A approved medicine
(Approval lapsed) ONPATTRO Patisiran 10 mg/5 mL (2mg/mL) solution for intravenous infusion single-dose vial (USA)
Section 19A approval holder
Medison Pharma Australia Pty Ltd ABN 19 659 723 403
Phone
1800 566 020
Approved until
Status
Expired
Medicines in short supply/unavailable
ONPATTRO patisiran 10 mg/5 mL concentrated injection for infusion vial - ARTG 380813
Indication(s)
Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Images
